Benefits From Antidepressants Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine

Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Archives of general psychiatry (Impact Factor: 14.48). 03/2012; 69(6):572-9. DOI: 10.1001/archgenpsychiatry.2011.2044
Source: PubMed


Some meta-analyses suggest that efficacy of antidepressants for major depression is overstated and limited to severe depression.
To determine the short-term efficacy of antidepressants for treating major depressive disorder in youth, adult, and geriatric populations.
Reanalysis of all intent-to-treat person-level longitudinal data during the first 6 weeks of treatment of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride.
All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine.
Children's Depression Rating Scale-Revised scores (youth population), Hamilton Depression Rating Scale scores (adult and geriatric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults, 960 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release venlafaxine.
Patients in all age and drug groups had significantly greater improvement relative to control patients receiving placebo. The differential rate of improvement was largest for adults receiving fluoxetine (34.6% greater than those receiving placebo). Youths had the largest treated vs control difference in response rates (24.1%) and remission rates (30.1%), with adult differences generally in the 15.6% (remission) to 21.4% (response) range. Geriatric patients had the smallest drug-placebo differences, an 18.5% greater rate of improvement, 9.9% for response and 6.5% for remission. Immediate-release venlafaxine produced larger effects than extended-release venlafaxine. Baseline severity could not be shown to affect symptom reduction.
To our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression. The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients. Baseline severity was not significantly related to degree of treatment advantage over placebo.

Download full-text


Available from: J. John Mann, Aug 11, 2014
    • "In addition, it is possible that medication is prescribed for a variety of conditions associated with a referral to psychiatric services not directly linked to self-injurious behavior in any case, exploration of potential medication effects on suicidality is important as there has been some evidence for increased risk of self-harm among young people aged under 18, who are taking serotonin reuptake inhibitors (SSRIs) for depression unlike other age groups (Martinez et al., 2005). However, this has been recently disputed in a reanalysis of all randomised placebo-control trials of fluoxetine and venlafaxine (Gibbons et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adolescents comprise a unique and often challenging group of patients with diverse presentations to the Mental Health Services; suicidal behavior being one of them. The main aim of this naturalistic project was to investigate demographic and clinical correlates of adolescent suicidal and self-harm events, which may be of value to decision-making in clinical practice. All adolescents (n = 149) registered and actively managed by a specialist community mental health service in South London were included in the study. Clinical information from their files was used to determine suicidality/self-harm events. The Columbia Classification Algorithm of Suicide Assessment (C-CASA) was utilised for classification purposes. Logistic regression was used to explore the effects of age, sex, diagnosis, medication, substance use (alcohol and/or cannabis) and ethnicity on suicidality/self-harming behaviors. Age, sex and use of psychotropic medication were identified to play a significant role in determining the risk of engaging in self-harming behavior. The risk was higher with increasing age and female sex. Medication seemed to have a protective effect. Reporting a 20% prevalence of non-suicidal self-injury (NSSI) in our population, we highlight the importance of NSSI as a distinct diagnostic category. Our findings have implications for risk assessment and appropriate decision-making in clinical settings. Results are translatable and relevant to other metropolitan areas.
    No preview · Article · Jul 2015 · Journal of Mental Health
  • Source
    • "As a consequence patients suffering from mild depression are not deprived from the right to receive treatment with antidepressants, However, this is an incorrect assumption based of inappropriate methods of analysis. A recent metaanalysis of data at the patient level suggested that initial severity plays no role [117]. Furthermore, a careful multiple treatments meta-analysis of the Kirsch [12] data set rejected initial severity as a factor that should dictate the treatment options [17] . "
    [Show abstract] [Hide abstract]
    ABSTRACT: During the last decade, several meta-analytic studies employing different methodological approaches have had inconsistent conclusions regarding antidepressant efficacy. Herein, we aim to comment on methodological aspects that may have contributed to disparate findings. We initially discuss methodological inconsistencies and limitations related to the conduct of individual antidepressant randomized controlled trials (RCTs), including differences in allocated samples, limitations of psychometric scales, possible explanations for the heightened placebo response rates in antidepressant RCTs across the past two decades as well as the reporting of conflicts of interest. In the second part of this article, we briefly describe the various meta-analyses techniques (e.g., simple random effects meta-analysis and network meta-analysis) and the application of these methods to synthesize evidence related to antidepressant efficacy. Recently published antidepressant metaanalyses often provide discrepant results and similar results often lead to different interpretations. Finally, we propose strategies to improve methodology considering real-world clinical scenarios.
    Full-text · Article · Jun 2015 · Current Neuropharmacology
  • Source
    • "However, there are several limitations to the reported meta-analyses. First, they rely on a limited number of studies, thus Gibbons et al. (2012) included 4 geriatric studies, whereas Nelson et al. (2013) included 10 trials of second-generation antidepressants in patients with late-life depression. Second, the authors included only a restricted range of baseline severity scores as they focused on MDD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Baseline severity is a crucial moderator of trial outcomes in adult depression, with the advantage of antidepressants over placebo increasing as severity increases. However, this relationship has not been examined in late-life depression. PubMed, Embase, Web of Science, PsycINFO, and Cochrane were searched for studies published through September 2014. Randomized, acute phase, and double-blind studies comparing an antidepressant group with a placebo group in depressed elderly patients were included. Nineteen studies met all inclusion criteria. Within-group effect sizes revealed significant improvement in antidepressant groups (g=1.35, p<.000), as well as in placebo groups (g=.96, p<.000). Change in depressive symptoms assessed by Hamilton Depression Rating Scale (HDRS) was moderated by baseline severity in antidepressant groups (Z=2.67, p=.008) and placebo groups (Z=4.46, p<.000). However, this would be expected as a result of regression toward the mean, and mean differences between groups did not increase (r=.19, p=.469) as a function of baseline severity. Limited to published data and information was only analyzed at the level of treatment groups. Baseline severity was not associated with an antidepressant-placebo difference and placebo responses are large in the treatment of depressed elderly people. We propose a stepwise approach, i.e., to initially offer elderly depressed patients psychosocial interventions and only consider antidepressants if patients do not respond. Copyright © 2015 Elsevier B.V. All rights reserved.
    Full-text · Article · Apr 2015 · Journal of Affective Disorders
Show more